We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant‐ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105.
- Authors
Suzuki, Tomotaka; Maruyama, Dai; Machida, Ryunosuke; Kataoka, Tomoko; Fukushima, Noriyasu; Takayama, Nobuyuki; Ohba, Rie; Omachi, Ken; Imaizumi, Yoshitaka; Tokunaga, Masahito; Katsuya, Hiroo; Yoshida, Isao; Sunami, Kazutaka; Kurosawa, Mitsutoshi; Kubota, Nobuko; Morimoto, Hiroaki; Kobayashi, Miki; Yamamoto, Kazuhito; Kameoka, Yoshihiro; Kagami, Yoshitoyo
- Abstract
Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105 In the National Cancer Research Institute (NCRI) Myeloma XI trial that was the training set for establishing the MRP, transplant-ineligible patients were treated with IMiDs-based induction regimens,[8] whereas all patients in JCOG1105 were treated with MPB. To the editor, The treatment outcomes of patients with multiple myeloma (MM) are heterogeneous; thus, several myeloma-related[[1]] and patient status-related risk factors[[3]] were investigated.
- Subjects
MULTIPLE myeloma; PREDNISOLONE; MELPHALAN; BORTEZOMIB; CLINICAL trials; PLASMACYTOMA
- Publication
Hematological Oncology, 2023, Vol 41, Issue 3, p590
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3103